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Angiomyolipoma (AML) is a relatively rare benign tumor of the kidney consisting
of fat, blood vessels, and smooth muscle. According to previous literature, AML
is predominant in women and approximately 20% occurs in patients with tuberous
sclerosis complex (TSC), in which 80% is bilateral or multiple.1-3 TSC is an auto-
somal disease entity with various features such as mental retardation, adenoma
sebaceum, seizure, and renal manifestations. Renal manifestations include AML,
Original Article DOI 10.3349/ymj.2010.51.5.728pISSN: 0513-5796, eISSN: 1976-2437 Yonsei Med J 51(5):728-734, 2010
Trends of Presentation and Clinical Outcome 
of Treated Renal Angiomyolipoma
Kyo Chul Koo,1 Won Tae Kim,2 Won Sik Ham,1 Jin Sun Lee,1 Hee Jeong Ju,1 and Young Deuk Choi1
1Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul;
2Department of Urology, Chungbuk National University College of Medicine, Cheongju, Korea.
Purpose: The purpose of this study is to set guidelines for the management of
renal angiomyolipoma (AML), clinical prognosis according to tumor size, in
association with tuberous sclerosis complex (TSC), multiplicity, radiographic
finding, and treatment modality. Materials and Methods: Between March 1998
and October 2008, 129 out of 254 patients with AML who underwent surgical
intervention or angioembolization were enrolled. Diagnosis of AML was deter-
mined by the presence of a low attenuated component on CT imaging or by
pathological confirmation. Indications of treatment were intractable pain, hematuria,
suspicion of malignancy, large tumor size, spontaneous rupture, and radiogra-
phically equivocal tumors in which a differential diagnosis was needed to rule out
malignancy. Parameters including age, sex, tumor size, multiplicity, radiographic
characteristics, association with TSC, and treatment modality were reviewed.
Results: Age at presentation was 50.6 years and mean tumor size was 3.5 cm.
Presentation symptoms were flank pain, hematuria, spontaneous rupture, and
fatigue. 97 (75.2%) patients were incidentally discovered. 100 (77.5%) were
females. 68 (52.7%) underwent nephron-sparing surgery (NSS), 35 (27.1%)
radical nephrectomy, and 26 (20.2%) angioembolization. TSC was accompanied
in 12 (9.3%) patients. No patient developed renal function impairment during the
mean follow-up period of 64.8 months. Patients with TSC presented at a younger
age, along with larger, bilateral, and multiple lesions. Conclusion: Significant
differences in clinical manifestations and treatment outcomes were noted in
respect to tumor characteristics, association with TSC, and treatment modality.
Considering the benign nature of AML, these parameters ought to be considered
when deciding upon active surveillance or prophylactic intervention.
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INTRODUCTION
benign cyst, and renal cell carcinoma (RCC), which is the
leading cause of morbidity and mortality in these patients.4
Although clinically-insignificant AMLs can be safely
observed, intervention is recommended for intractable pain,
large size, suspicion of malignancy, and risk of life-threa-
tening hemorrhages.5-7 Given the benign nature of AML,
renal preserving treatment modalities such as nephron-
sparing surgery (NSS) or selective renal artery angioemboli-
zation are preferred.6 To set a strategy for AML manage-
ment, clinical prognosis according to tumor size, association
with TSC, multiplicity, radiologic finding, and treatment
modality were investigated.
Patient demographics
Upon approval from the Yonsei University Health System
Institutional Review Board, complete data were available
for 254 patients diagnosed of renal AML between March
1998 and October 2008. Among these patients, 129
patients who have been treated by surgery or angioem-
bolization were identified. The diagnosis of AML was
determined either by the presence of a low attenuated
component on CT imaging or by pathological confir-
mation through NSS or radical nephrectomy. The cutoff
value of -10 Hounsfield units was used to differentiate
AMLs between classic and fat poor. TSC was suspected in
patients with facial angiofibromas, mental retardation,
seizure, or pulmonary lymphangiomyomatosis, and were
categorized as definite when positive for TSC1 and TSC2
loss of heterozygosity.
Criteria standards
All 129 patients had complete charting records along with
triphasic CT scan imaging. Parameters including age, sex,
tumor size, multiplicity, radiologic characteristics, associa-
tion with TSC, and treatment modalities were retrospec-
tively reviewed. Tumor size was identified as the greatest
dimension recorded on preoperative CT scan. The growth
of lesions was estimated with the first and last imaging
study. Indications of treatment were intractable pain, hema-
turia, suspicion of malignancy, large tumor size, spontan-
eous rupture, and radiographically equivocal tumors in
which a differential diagnosis was needed to rule out mali-
gnancy. NSS or radical nephrectomy was chosen as the
surgical modality. NSS was performed for tumors < 4 cm,
tumors in a solitary kidney, multiple or bilateral tumors, or
in compromised renal function patients whose renal paren-
chyma resection should be minimized. Radical nephrec-
tomy was performed for tumors ≥ 4 cm or complex renal
tumors including completely endophytic or hilar tumors
within 5 mm from hilar vessels.
Statistical analysis
Student’s t-test and Pearson’s chi-square test were used for
analysis of continuous and categorical variables, respecti-
vely. All tests were two sided, and p values < 0.05 were
considered statistically significant. The Statistical Package
for Social Sciences software, version 12 (SPSS Inc, Chicago,
IL, USA) was used for statistical analysis. 
Patient demographics
Age at presentation was 50.6 ± 13.7 years; 100 were
females and 29 were males. The prevalence of AML was
highest in the fifth decade (n = 41, 31.8%). TSC was pre-
sent in 12 patients whose age at presentation was 30.1 ±
12.1 years. The lesion was incidentally discovered in 97
patients and was revealed due to symptoms in 32 patients.
Chief complaints included flank pain, hematuria, fatigue,
and shock due to spontaneous rupture. 112 had single
lesions on imaging whereas 17 and 11 patients had multi-
ple and bilateral lesions, respectively (Table 1).
Comparison between sporadic and TSC associated 
AML
The differences of clinical spectrum in between sporadic
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MATERIALS AND METHODS
Table 1. Patient Characteristics
Characteristics No. of patients %
Sex
Male 29 22.5
Female 100 77.5
Age (yrs)
Mean ± SD 50.6 ± 13.7
Range 12 - 76
Symptoms at presentation
Asymptomatic 97 75.2
Symptomatic 32 24.8
Flank pain 20 62.5
Gross hematuria 7 21.8
Fatigue 3 9.5
Spontaneous rupture     2 6.2
Multiplicity
Single 112 86.8
Multiple / bilateral 17 13.2
Tuberous sclerosis complex
Negative 117 90.7
Positive   12 9.3
RESULTS
and TSC associated AMLs were investigated. Patients
with TSC associated AMLs were significantly younger at
presentation, had a larger tumor, had more multiple and
bilateral lesions, and were mostly symptomatic at presenta-
tion (p < 0.001). However, there were no significant dif-
ferences of gender distribution between the two groups (p
= 0.273). Surgical treatment tended towards a significantly
higher rate in sporadic AMLs, which were equivocal with
malignancy. Due to the preference of radical surgery in
large-sized tumors, more sporadic AMLs were treated with
NSS while more TSC-associated AMLs were managed
with radical nephrectomy. A significant shift was found
towards angioembolization in patients with TSC-associa-
tion (p < 0.001). An interesting group included 4 TSC-
associated patients with tumors ≥ 8 cm, in which 1 and 3
patients received angioembolization and radical nephrec-
tomy due to spontaneous rupture, respectively. However a
radical nephrectomy was eventually performed in the pati-
ent who previously underwent angioembolization because
of intractable control of hemorrhages. With respect to
lymph node involvement, preoperative CT scans revealed
a significantly higher rate of lymph node enlargement in
TSC-associated AMLs (p < 0.001) (Table 2).
Characteristics according to tumor size
To determine the potential difference in clinical outcomes
according to tumor size, the subsets were analyzed by a
cutoff size of 4 cm. Tumors ≥ 4 cm were more commonly
symptomatic, associated with TSC, and occurred in younger
patients. 82 patients with tumors < 4 cm were mostly
treated by NSS (n = 61, 92.4%). Among these patients, 3
underwent staged NSS for bilateral tumors and 1 under-
went NSS for resection of two ipsilateral tumors. Radical
nephrectomy was inevitable in 5 patients due to comple-
tely endophytic or hilar tumors located adjacent to the
major branches of the renal vessels. 47 patients with
tumors ≥ 4 cm were mostly treated by radical nephrectomy
(n = 26, 81.2%). Our series of AML revealed a trend for
NSS in small sized tumors, while large tumors tended to
be managed by radical nephrectomy, angioembolization,
or both (p < 0.001) (Table 3).
Comparison between single and multiple AMLs
Several features differentiated patients with single AMLs
from those with multiple AMLs including age, presence of
symptoms, tumor size, and association with TSC. Patients
with multiple AML were significantly younger, more sym-
ptomatic, larger, and were more associated with TSC. Mo-
reover, radiographically-diagnosed AMLs composed 66.1%
and 82.3% of single and multiple AMLs, respectively.
With respect to treatment modality, surgical intervention
including NSS or radical nephrectomy was more commo-
nly performed in single AMLs while angioembolization
was preferred in multiple AMLs (p < 0.001) (Table 4).
Comparison between radiographic subtypes: classic
and fat poor
Surgical treatment was performed in 62 patients with
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Table 2. Differences of Patient Characteristics between Sporadic and Tuberous Sclerosis (TS)-Associated AML
Sporadic AML (n = 117) TS-associated AML (n = 12) p value
Age (yrs) 52.6 ± 12.1 30.1 ± 12.1 < 0.001*
No. of female (%) 92 (78.6) 8 (66.7) 0.273�
Mean tumor size (cm) 3.7 ± 2.5 7.6 ± 4.3 < 0.001*
Size range (cm) 0.8 - 11.7 1.1 - 16
Symptomatic at presentation (%) 21 (17.9) 11 (91.7) < 0.001�
Multiple (%) 8 (6.8) 9 (75.0) < 0.001�
Bilateral (%) 3 (2.6) 8 (66.7) < 0.001�
Radiologic appearance (%) 0.238�
Classic AML 78 (66.7) 10 (83.3)
Fat poor AML 39 (33.3) 2 (16.7)
Surgical intervention (%) 96 (82.1) 7 (58.3) 0.002�
Nephron sparing surgery 67 (69.7) 1 (14.2)
Radical nephrectomy 29 (30.3) 6 (85.8)
Embolization (%) 21 (17.9) 5 (41.7) < 0.001�
Lymph node involvement (%) 5 (4.3) 4 (33.3) < 0.001�
AML, angiomyolipoma.
Data presented as mean ± standard deviation or numbers.
*Student’s t-test.
�Pearson’s chi-square test.
radiographic characteristics indicating AML. All patients
with fat poor AMLs who underwent prophylactic surgery
on suspicion of malignancy were finally diagnosed with
pathological AMLs. Although classic AMLs tended to be
more symptomatic, multiple, and larger compared to fat
poor AMLs, there were no significant differences in res-
pect to age and gender distribution (Table 5).
Characteristics according to lymph node involvement
Characteristics of AMLs according to presence of radio-
graphic lymph node enlargement were analyzed. Among
the 9 patients who received a lymphadenectomy, the lymph
nodes of 3 patients were pathologically proven to be AML.
AMLs with radiographic lymph node enlargement tended
to be more symptomatic, multiple, bilateral, and more com-
monly accompanied by TSC. There were no statistically
significant differences according to tumor size.
Clinical outcomes
The mean follow-up period was 64.8 months (range, 11-97
months). Of the 129 patients who received treatment of
any kind, surgery and angioembolization were performed
in 103 (79.8%) and in 26 (20.2%) patients, respectively.
Despite repeated NSS or angioembolization, renal units
retained adequate function to maintain serum creatinine at
the normal range in all patients during the follow-up
Trends of Treated Renal Angiomyolipoma
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Table 4. Differences of Patient Characteristics According to Tumor Multiplicity
Single Multiple p value*
Patients 112 17
Age (yrs) 50.3 ± 13.1 35.0 ± 12.6 < 0.001*
No. of female (%) 88 (78.5) 12 (70.5) 0.463�
Symptomatic at presentation (%) 21 (18.7) 11 (64.7) < 0.001�
Tumor size (cm) 3.8 ± 2.7 6.0 ± 3.9 0.003*
Size range (cm) 0.8 - 12 1.1 - 16
Radiographic appearance (%) 0.011�
Suspected AML 74 (66.1) 14 (82.3)
Fat poor AML 38 (33.9) 3 (17.7)
Tuberous sclerosis complex (%) 3 (2.3) 9 (52.9) < 0.001�
Surgical intervention (%) 93 (83) 10 (58.8) < 0.001�
Nephron sparing surgery 65 (69.8) 3 (30)
Radical nephrectomy 28 (30.2) 7 (70)
Embolization (%) 19 (17) 7 (41.2) < 0.001�
AML, angiomyolipoma.
Data presented as mean ± standard deviation or numbers.
*Student’s t-test.
�Pearson’s chi-square test.
Table 3. Differences of Patient Characteristics According to Tumor Size
Variable
Tumor size
p value*
< 4 cm ≥ 4 cm
Patients 82 47
Age at presentation (yrs) 52.4 ± 12.7 47.1 ± 14.8 0.034*
Mean tumor size (cm) 2.2 ± 0.8 7.3 ± 2.5
Size range (cm) 0.8 - 3.7 4 - 16
Symptomatic at presentation (%) 12 (14.6) 20 (42.5) < 0.001�
Tuberous sclerosis complex (%) 3 (3.6) 9 (19.1) 0.004�
Surgical intervention (%) 66 (80.0) 32 (68.0) < 0.001�
Nephron sparing surgery 61 (92.4) 6 (18.8)
Radical nephrectomy 5 (7.6) 26 (81.2)
Embolization (%) 16 (19.5) 15 (31.9) < 0.001�
Data presented as mean ± standard deviation or numbers.
*Student’s t-test.
�Pearson’s chi-square test.
period. Although 122 patients (94.5%) remained asympto-
matic during the follow-up, 7 (5.5%) patients necessitated
additional treatment. 5 patients (3.8%) were refractory to
angioembolization and tumor lesions grew at an average
rate of 2.3 cm/year. These patients were followed by NSS
and angioembolization in 2 and 3 patients, respectively. In
1 patient, angioembolization failed to reduce the size of a
spontaneously-ruptured tumor at the 3 month follow-up
and re-embolization was thus performed. In 1 female
patient who underwent NSS for a 6 cm-sized TSC-asso-
ciated AML, a radical nephrectomy was performed after
the 23 month follow-up due to the spontaneous rupture of
a recurred tumor in the ipsilateral kidney. The average tumor
size of the 7 patients who required such secondary treat-
ment during the follow-up was 9.9 cm, of which 4 (57.1%)
were TSC-associated patients.
AMLs are recognized as hamartomatous lesions composed
of heterogenous tissue components including blood vessels,
smooth muscles, and fat. Renal AMLs occupy 1-3% of
renal tumors and occur in 2 clinical spectrums: sporadic
and those associated with TSC.8 TSC is an autosomal
disease entity with various characteristics such as mental
retardation, adenoma sebaceum, seizure, renal manifesta-
tions, and loss of heterozygosity of TSC1 and TSC2 genes.4,9
Although AML is uncommon among the general popula-
tion, previous studies has shown that 20% of patients with
TSC are known to develop AML while on the other hand,
more than 50% of AMLs are associated with TSC.7 In this
rare setting, tumors tend to be larger, develop earlier in life,
and are more often multiple or bilateral.3
Our study demonstrated a relatively low prevalence rate
for TSC-associated AMLs (9.3%) compared with 20%
reported by Lendvay and Marshall.10 However, significant
differences in the clinical spectrum of TSC-association
according to age at presentation, tumor size, symptom, and
multiplicity correlated with those of previous studies.7
TSC-associated AMLs tended to be more symptomatic,
multiple, and bilateral. Therefore, active surveillance is
strongly recommended for asymptomatic tumors < 4 cm,
while angioembolization or surgical interventions with
Kyo Chul Koo, et al.
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DISCUSSION
Table 5. Differences of Patient Characteristics between Classic and Fat Poor AML
Classic AML Fat poor AML p value*
Patients 88 41
Age (yrs) 50.7 ± 13.3 50.1 ± 14.7 0.641*
No. of female (%) 67 (76.1) 33 (80.4) 0.581�
Symptomatic at presentation (%) 27 (30.6) 5 (12.1) 0.024�
Multiplicity (%) 14 (15.9) 3 (7.3) 0.011�
Tumor size (cm) 4.8 ± 3.1 2.4 ± 1.7 0.007*
AML, angiomyolipoma.
Data presented as mean ± standard deviation or numbers.
*Student’s t-test.
�Pearson’s chi-square test.
Table 6. Differences of Patient Characteristics According to Presence of Lymph Nodes (LN)
LN involvement (-) LN involvement (+) p value*
Patients 120 9
Tumor size (cm) 4.0 ± 2.9 5.5 ± 3.4 0.234*
Symptomatic at presentation (%) 27 (22.5) 5 (55.5) 0.027�
Multiple (%) 13 (10.8) 4 (44.4) 0.004�
Bilateral (%) 8 (6.6) 3 (33.3) 0.006�
Tuberous sclerosis complex (%) 8 (6.6) 4 (44.4) < 0.001�
Surgical intervention (%) 94 (78.3) 9 (100) < 0.001�
Nephron sparing surgery 65 (69.1) 3 (33.3)
Radical nephrectomy 29 (30.9) 6 (66.7)
Embolization (%) 26 (21.7) 0 (0) < 0.001�
Data presented as mean ± standard deviation or numbers.
*Student’s t-test.
�Pearson’s chi-square test.
maximal parenchymal preservation including partial
nephrectomy, enucleation, or wedge resection should be an
alternative option for symptomatic tumors ≥ 4 cm. We
reported a relatively large average tumor size for TSC-
associated AML patients (7.6 cm, range, 1.1-16 cm) com-
pared with 6.6 cm reported by Harabayashi, et al.11 Our
experience of 4 TSC-associated patients with tumors ≥ 8
cm who finally ended up with receiving a radical nephrec-
tomy demonstrated that, although angioembolization could
be a primary option in controlling existing or impending
hemorrhages in spontaneous ruptured AMLs, a prophy-
lactic radical nephrectomy is relatively recommended for
tumors ≥ 8 cm or those refractory to angioembolization.
Among TSC-associated AMLs, epitheliod components
were pathologically observed in 9 patients. These tumors
are thought to originate from common progenitor perivas-
cular epitheloid cells, recognized as members of the peri-
vascular epithelioid clear cell tumors (PEComas).12 Unlike
classic AMLs, PEComas are distinctively characterized by
local recurrence, lymph node involvement, and metastasis,
thus demonstrating a substantial diagnostic challenge in
differentiation with RCC.12-14 Brecher, et al.15 reported their
results with AML with lymph node involvement, that no
recurrence was noted during the follow-up and that it repre-
sents a multicentric growth pattern rather than metastasis.
In addition, prognosis was considered to depend on remai-
ning renal function rather than lymph node involvement.15
However, our study included one 16 year-old female patient
who was an exception to this thesis. She presented with a 7
cm solid fat-containing parenchymal mass with multiple
lymph node involvement along with facial adenoma seba-
ceum and multiple pulmonary lymphangioleiomatosis.
Although NSS was performed due to her young age and
disease trait, a radical nephrectomy was eventually perfor-
med after the 23 month follow-up due to a spontaneous
rupture of the recurred tumor in the ipsilateral kidney.
Although the patient remained asymptomatic for a follow-
up period of 49 months, angioembolization or a radical
nephrectomy is currently being considered for a 16 cm-
sized recurred tumor on the contralateral kidney.
With the advancement of noninvasive radiological
imaging techniques, the detection of fat poor AMLs has
recently surged in line with increased detection of incidental
and asymptomatic small sized renal tumors.16 Although the
diagnosis of AML is typically based upon presence of fat
component on CT scans, many AMLs with a scant fat
component may evade radiographic diagnosis.17,18 Fergany,
et al.19 described that solid renal tumors ought to be primarily
considered as RCCs and surgical intervention are perfor-
med, due to the fact that solid tumors originating from
renal parenchyma are mostly malignant and that 85-90%
are RCCs.20 McCullough, et al.21 also recommended surgi-
cal treatment for tumors that are undistinguishable from
RCC or those that contain calcification, a feature implying
malignancy. Also, Lemaitre, et al.17 stated that 14% of
AMLs demonstrate low fat content on radiographic imag-
ing. However, of 129 AMLs in our series, 41 (31.7%) had
radiographic features prompting surgical management
based on clinical suspicion of RCC; all 41 cases were sur-
gically managed based on the previously established
principle.
Through our retrospective review of clinical outcomes
of AML, we noticed a treatment trend based on tumor
characteristics along with its associated symptoms. Altho-
ugh surgical intervention such as NSS or radical nephrec-
tomy was the mainstay in the management of most renal
tumors, our study demonstrated an surging number of
angioembolization in patients with TSC-association. Seve-
ral factors led to this conservative approach in recent years.
Repeated nephrectomy reduces management options for
the remaining kidney, subsequently mandating only a
conservative approach. Regardless, characteristics of TSC-
associated AMLs such as large size and multiplicity have
limited the role of NSS. Angioembolization and NSS for
renal AMLs both offer long-term renal function preserva-
tion with low complication rates. However, to better define
the advantages of these two modalities a prospective head-
to-head, comparisons will be needed.7,22,23
In conclusion, significant differences in clinical manifes-
tations and treatment outcomes of AML were noted accord-
ing to tumor size, association with TSC, multiplicity, radi-
ologic characteristics, and treatment modalities. However,
most patients treated for AML remained symptom-free
with preservation of renal function. The fact that small-
sized AMLs with scant fat components and those asso-
ciated with TSC may evade radiographic diagnosis is of
clinical significance. Therefore, additional areas of resea-
rch need to address the role of conventional imaging in
identifying a fat component that would better differentiate
AML from malignancy.
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